Frankfurt - Delayed Quote EUR

Biosynex SA (0DL.F)

Compare
1.4700
-0.0820
(-5.28%)
As of 8:17:04 AM GMT+2. Market Open.
Loading Chart for 0DL.F
  • Previous Close 1.5520
  • Open 1.4700
  • Bid 1.4840 x --
  • Ask 1.5160 x --
  • Day's Range 1.4700 - 1.4700
  • 52 Week Range 1.0500 - 6.6300
  • Volume 300
  • Avg. Volume 11
  • Market Cap (intraday) 27.095M
  • Beta (5Y Monthly) 0.28
  • PE Ratio (TTM) --
  • EPS (TTM) -2.8600
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date May 16, 2022
  • 1y Target Est --

Biosynex SA designs, manufactures, and distributes rapid diagnostic tests in France and internationally. The company offers medical devices for in vitro diagnosis in the form of rapid diagnostic tests, immunoblots, molecular biology, and point of care products for screening, diagnosis, and prevention in the areas of bacteriology, parasitology, mycology, virology, biochemistry and oncology, and women's health, as well as COVID-19 tests and instruments. It also provides self-tests; self-measurement products, including thermometers, oxymeters, and blood pressure monitors; and oral care and medical aid products. The company provides its products to biology and medical analysis laboratories, hospitals, pharmacies, hyper and supermarkets, etc. It also exports its products internationally. The company was founded in 1993 and is based in Illkirch-Graffenstaden, France.

www.biosynex.com

515

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 0DL.F

View More

Performance Overview: 0DL.F

Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .

YTD Return

0DL.F
14.31%
CAC 40 (^FCHI)
1.17%

1-Year Return

0DL.F
68.39%
CAC 40 (^FCHI)
10.52%

3-Year Return

0DL.F
92.16%
CAC 40 (^FCHI)
8.36%

5-Year Return

0DL.F
92.93%
CAC 40 (^FCHI)
75.57%

Compare To: 0DL.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 0DL.F

View More

Valuation Measures

Annual
As of 4/3/2025
  • Market Cap

    27.83M

  • Enterprise Value

    79.97M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.20

  • Price/Book (mrq)

    0.28

  • Enterprise Value/Revenue

    0.77

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -36.97%

  • Return on Assets (ttm)

    -7.13%

  • Return on Equity (ttm)

    -31.52%

  • Revenue (ttm)

    104.07M

  • Net Income Avi to Common (ttm)

    -38.48M

  • Diluted EPS (ttm)

    -2.8600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    10.74M

  • Total Debt/Equity (mrq)

    61.07%

  • Levered Free Cash Flow (ttm)

    -7.73M

Research Analysis: 0DL.F

View More

Company Insights: 0DL.F

Research Reports: 0DL.F

View More

People Also Watch